stella
beta
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia — Stella
Home
/
Primacy Immune Thrombocytopenia
/
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
View on ClinicalTrials.gov
Recruiting
Back to Primacy Immune Thrombocytopenia trials
Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(1 site)
China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu